Evidence map›Paper›PMID 40222595›Full record

Observational studyRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2025

Externally validated digital decision support tool for time-to-osteoradionecrosis risk-stratification using right-censored multi-institutional observational cohorts.

Laia Humbert-Vidan, Serageldin Kamel, Andrew Wentzel, Zaphanlene Kaffey, Moamen Abdelaal, Kyle B Spier, Natalie A West, G Elisabeta Marai, Guadalupe Canahuate, Xinhua Zhang and 30 more

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Advancing Normal Tissue Complication Probability Modeling with Supervised Contrastive Learning for Predicting Osteoradionecrosis.Proceedings of the ... Symposium on Applied Computing. Symposium on Applied Computing · 2026
    Article
  4. Review
  5. Article
  6. Lessons from the Development and Deployment of an Interactive Oncological Risk Estimator.... IEEE Workshop on Visual Analytics in Healthcare. IEEE Workshop on Visual Analytics in Healthcare · 2025
    Article
  7. FlavorCharter: Development of a Smartphone App for Quantifying Food Flavor.Proceedings ... ICDM workshops. IEEE International Conference on Data Mining · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Laia Humbert-VidanThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Serageldin KamelThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew WentzelUniversity of Illinois Chicago, Chicago, IL, USA.
Zaphanlene KaffeyThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Moamen AbdelaalEmory School of Medicine, Atlanta, GA, USA.
Kyle B SpierPaul L. Foster School of Medicine, El Paso, TX, USA.
Natalie A WestThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
G Elisabeta MaraiUniversity of Illinois Chicago, Chicago, IL, USA.
Guadalupe CanahuateUniversity of Iowa, Iowa City, IA, USA.
Xinhua ZhangUniversity of Illinois Chicago, Chicago, IL, USA.
Melissa M ChenThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kareem A WahidThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jillian RigertThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Seyedmohammadhossein HosseinianNorth Carolina State University, Raleigh, NC, USA.
Andrew J SchaeferRice University, Houston, TX, USA.
Kristy K BrockThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark ChambersThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adegbenga O OtunThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruth Aponte-WessonThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vinod PatelGuy's and St Thomas' NHS Foundation Trust, London, UK.
Andrew HopeUniversity of Toronto, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Jack PhanThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adam S GardenThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steven J FrankThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William H MorrisonThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael T SpiottoThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David RosenthalThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anna LeeThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Renjie HeThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mohamed A NaserThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Erin WatsonPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Katherine A HutchesonThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abdallah S R MohamedThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vlad C SandulacheBaylor College of Medicine, Houston, TX, USA.
Lisanne V van DijkUniversity Medical Center Groningen, Groningen, the Netherlands.
Amy C MorenoThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Teresa Guerrero UrbanoGuy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: teresa.guerrerourbano@gstt.nhs.uk.
Clifton D FullerThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: cdfuller@mdanderson.org.
Stephen Y LaiThe University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: sylai@mdanderson.org.
MD Anderson Head and Neck Cancer Symptom Working Group

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2019 to 2023
$11.0M
Project 3: OPC-RADP01CA285249 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Carly E. A. Barbon · 2024 to 2026
$9.4M
Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac deviceR01DE028290 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTODOULEAS, JOHN PAUL, FULLER, CLIFTON DAVID · 2019 to 2023
$4.3M
Integration and interoperability of complex data and tissues from the human brainUG3TR004501 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LOEB, JEFFREY A · 2023 to 2025
$3.1M
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR01DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2016 to 2020
$2.9M
Longitudinal Spatial-Nonspatial Decision Support for Competing Outcomes in Head and Neck Cancer TherapyR01CA258827 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2021 to 2025
$2.9M
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)U01DE032168 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Clifton David Fuller, STEPHEN Y LAI · 2023 to 2026
$2.8M
SCH: Personalized Rescheduling of Adaptive Radiation Therapy for Head & Neck CancerR01CA257814 · NCI · RICE UNIVERSITY · PI FULLER, CLIFTON DAVID, SCHAEFER, ANDREW J · 2021 to 2024
$1.8M
Image Guided Cancer Therapy Training ProgramT32CA261856 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kristy Brock, Clifton David Fuller · 2022 to 2026
$1.2M
Provider and Patient-generated Remote Oro-Dental Health Electronic Data Capture for Algorithmic Longitudinal Evaluation and Risk-Assessment (PROHEALER)K01DE030524 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MORENO, AMY CATHERINE · 2022 to 2024
$479k
NCATS NIH HHS UG3 TR004501NCI NIH HHS K12 CA088084NCI NIH HHS P01 CA285249NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221707NCI NIH HHS R01 CA257814NCI NIH HHS R01 CA258827NCI NIH HHS T32 CA261856NIDCR NIH HHS K01 DE030524NIDCR NIH HHS R01 DE025248NIDCR NIH HHS R01 DE028290NIDCR NIH HHS R21 DE031082NIDCR NIH HHS U01 DE032168
6 · The paper itself

Abstract

backgroundExisting studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has important implications to monitor oral health in head and neck cancer (HNC) long-term survivors.

methodsData were retrospectively obtained for a clinical observational cohort of 1129 patients (198 ORNJ cases) with HNC treated with radiotherapy (RT) at The University of Texas MD Anderson Cancer Center. A Weibull Accelerated Failure Time model was trained on previously identified dosimetric, clinical and demographic predictors. External validation was performed using an independent cohort of 265 patients (92 ORNJ cases) treated at Guy's and St. Thomas' Hospitals. To facilitate clinical implementation of the model, an online graphical user interface (GUI) was developed, including formal stakeholder usability testing.

resultsOur model identified that gender (males), pre-RT dental extractions and D25% were associated with a 38 %, 27 % and 12 % faster onset of ORNJ, respectively, with adjusted time ratios of 0.62 (p = 0.11), 0.73 (p = 0.13) and 0.88 (p < 0.005). The model demonstrated strong internal calibration (integrated Brier score of 0.133, D-calibration p-value 0.998) and optimal discrimination at 72 months (Harrell's C-index of 0.72).

conclusionThis study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose and patient-related factors not only on the probability of a late effect (ORNJ), but the conditional risk during survivorship.

Indexed as

Head and Neck NeoplasmsOsteoradionecrosisAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsDecision support toolHead and neck cancersNormal tissue complication predictionOsteoradionecrosis of the jawRadiation-induced toxicityRadiotherapyTime-to-event prediction models

Identifiers

PMID40222595
PMCPMC12085279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.